Roger Adsett Sells 42,975 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 42,975 shares of Insmed stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $3,378,264.75. Following the completion of the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at $11,483,506.02. This represents a 22.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Thursday, February 6th, Roger Adsett sold 45,605 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $3,689,444.50.
• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Trading Up 0.8 %

Shares of NASDAQ INSM opened at $79.31 on Friday. The stock’s 50 day moving average price is $73.38 and its two-hundred day moving average price is $73.27. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $82.04. The stock has a market capitalization of $14.19 billion, a P/E ratio of -14.29 and a beta of 1.11. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on INSM shares. JPMorgan Chase & Co. upped their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus upped their target price on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley upped their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.60.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its position in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC raised its position in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the period. Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter worth approximately $47,000. Finally, Exchange Traded Concepts LLC raised its position in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.